Dr. Olga Kubassova, CEO of IAG, interview on the RP HealthCast Podcast
The CEO of IAG, Dr. Olga Kubassova, guest starred on the RP HealthCast podcast on 24 Feb 2021.
The topic of the episode was ‘How AI is Revolutionizing Drug Discovery and Development’.
Dr. Olga Kubassova, the leading expert in imaging and AI in drug development discussed how IAG is using AI and Machine Learning to optimize the clinical trial process through its proprietary DYNAMIKA platform, and the advantages it provides in speed to market, lowered costs, and improved decision making.
Also featuring in the episode were Ed Miseta, the executive editor of Clinical Leader and Life Science Leader magazine, and Dr. David Horn Solomon, the CEO of Pharnext.
‘The purpose of AI is really that fast, speedy choice and more targeted precise choice. We want to analyze the data related to patient response in a way that the human eye can’t possibly see.’ said Dr. Olga Kubassova.
Listen here: https://rphealthcast.com/podcast/how-ai-is-revolutionizing-drug-discovery-and-development/
About The RP HealthCast Podcast
Science, innovation, and life. One story at a time. The RP HealthCast returns in 2021 with a fresh format, featuring captivating stories from innovators, journalists, medical professionals, and more! In each episode our host, Jeffrey Freedman, goes beyond the headlines to explore different perspectives and discuss varying viewpoints on the latest advancements in technology and health. Website: RPHealthCast.com
About Olga Kubassova
Dr. Olga Kubassova is a mathematician by background with MS in Mathematics from St. Petersburg State University, Russia, MS in Information Technology from Lappeenranta University of Technology, Finland and a PhD in Computer Science from the University of Leeds, UK.
Dr. Olga Kubassova is the founding scientist and CEO of IAG, Image Analysis Group, an imaging expert company. She started IAG straight after her PhD with an idea to bring the best of mathematics and computer science to optimize clinical development process while using imaging derived biomarkers to reliably and objectively assess efficacy of a novel drug.
Today IAG is a recognized partner to many blue-chip pharma companies in rheumatology, oncology and neurology. Since completing her PhD research in the area of MRI algorithm development for musculoskeletal disorders, Olga has been a significant contributor to the development of MRI as a clinical research and diagnostic tool in rheumatoid arthritis, osteoarthritis and other inflammatory joint diseases. She has co-authored over 60 articles, 7 book chapters and a number of abstracts that have built a significant evidence base for the medical imaging as a sensitive and objective biomarker for the assessment of various diseases and as an early measure of efficacy of new drugs. Olga is an active researcher, scientific adviser to the UK government and EU funding bodies, inc. European Commission, Innovative Medicines Initiative; she is an editor and reviewer of several scientific journals.
Olga is a renowned healthcare innovator and biotech investor, with passion for improving people’s health.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: wp1.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin